At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 495 enrolled
Drug / intervention
LY2216684 +1 moredrug
Likely dose
LY2216684 6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder
In Brief
A Phase 3 clinical trial evaluating LY2216684 and Placebo for Depressive Disorder, Major. Completed, enrolled 495 participants across 37 sites in 5 countries.
Detailed Summary
The purpose of this study is to assess whether LY2216684 is superior to placebo in the treatment of adult patients with major depressive disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
CountriesArgentina, Finland, Poland, Russia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2008
Enrollment StartDec 2008
Primary CompletionFeb 2010
Study CompletionMar 2011
TodayJul 2026
First PostedNov 21, 2008
Enrollment StartDec 1, 2008
Primary CompletionFeb 1, 2010
Study CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.6 years ago
Interventions
LY2216684drug
Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
Placebodrug
Dose: 3 tablets QD for 10 weeks